Review Article
Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
Table 2
The effect of selected agents on skeletal-related events (SREs) and pain palliation response based on randomized clinical trials.
| | Agent | SRE (% incidence or time to SRE) | Pain palliation response |
| | Docetaxel versus mitoxantrone [8] | NE | 35% versus 22% () | | Abiraterone acetate versus placebo [12, 13] | 25.0 versus 20.3 months () | 45% versus 28.8% () | | Enzalutamide versus placebo [11, 14] | 16.7 versus 13.3 months () | NR | | Cabazitaxel versus mitoxantrone [74] | NE | 9.2% versus 7.7% () | | Zoledronic acid versus placebo [5] | 33.2% versus 44.2% (), 14.9 months versus 10.7 months () | 7% bone pain index () | | Denosumab versus zoledronic acid [16] | 20.7 versus 17.1 months () | NE | | Denosumab versus placebo (non-mCRPC) [44] | 29.5 versus 25.3 months () | NE | | Sm-153 versus placebo [18] | NE | 72% pain relief () | | Sr-89 [53] | NE | Mean complete pain response 32%, mean partial pain response 44% | | Ra 223 versus placebo [21] | 15.6 versus 9.8 months () | NE | | Cabozantinib [67] | NE | 64% improvement |
|
|
NE: not examined and NR: not reported.
|
